Related Experiment Video
Updated: May 18, 2026
08:50
Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
Published on: January 9, 2026
Drug-associated thrombotic microangiopathies
Justin Kreuter1, Jeffrey L Winters
1Division of Transfusion Medicine, Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Seminars in Thrombosis and Hemostasis
|October 6, 2012
Summary
Thrombotic microangiopathy causes low platelets and red blood cell fragments, leading to organ damage. This review covers drug-induced causes and highlights plasma exchange as a treatment for this condition.
Area of Science:
- Hematology
- Pathology
- Pharmacology
Background:
- Thrombotic microangiopathy (TMA) is characterized by thrombocytopenia, schistocytes, and organ ischemia.
- Diverse etiological factors trigger TMA, targeting specific vascular beds.
- Understanding these causes is crucial for timely diagnosis and management.
Purpose of the Study:
- To review key drugs associated with thrombotic microangiopathy.
- To discuss newly identified drug-induced TMAs.
- To outline treatment strategies, emphasizing plasma exchange.
Main Methods:
- Literature review of drug-associated thrombotic microangiopathy.
- Analysis of pathological mechanisms and clinical presentations.
- Synthesis of current treatment guidelines.
Main Results:
- Identified classical and emerging drug culprits for TMA.
- Highlighted the varied clinical manifestations based on causative agents.
- Emphasized the critical role of plasma exchange in managing TMA.
Conclusions:
- Drug-induced thrombotic microangiopathy represents a significant clinical challenge.
- Prompt recognition of causative agents and initiation of appropriate therapy, particularly plasma exchange, are vital.
- Further research into novel therapeutic approaches is warranted.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Peripheral Artery Disease I: Introduction
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:26Transient Ischemic Attack l: Introduction
A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...